Medtronic Financial Statements (MDT)
|
|
|
|
Report date
|
|
|
23.06.2022 |
22.06.2023 |
20.06.2024 |
20.06.2025 |
18.06.2026 |
|
24.02.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
|
|
|
|
36 364 |
|
26 557 |
|
Operating Income, bln rub |
|
|
|
|
|
|
6 467 |
|
4 903 |
|
EBITDA, bln rub |
? |
|
|
|
|
|
9 809 |
|
7 081 |
|
Net profit, bln rub |
? |
|
|
|
|
|
4 800 |
|
3 557 |
|
|
OCF, bln rub |
? |
|
|
|
|
|
7 330 |
|
4 757 |
|
CAPEX, bln rub |
? |
|
|
|
|
|
1 904 |
|
1 416 |
|
FCF, bln rub |
? |
|
|
|
|
|
5 426 |
|
3 341 |
|
Dividend payout, bln rub
|
|
|
|
|
|
|
3 639 |
|
2 731 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
|
|
|
|
75.8% |
|
76.8% |
|
|
OPEX, bln rub |
|
|
|
|
|
|
17 179 |
|
11 299 |
|
Cost of production, bln rub |
|
|
|
|
|
|
12 721 |
|
10 354 |
|
R&D, bln rub |
|
|
|
|
|
|
2 873 |
|
2 202 |
|
Interest expenses, bln rub |
|
|
|
|
|
|
715.0 |
|
538.0 |
|
|
Assets, bln rub |
|
|
90 981 |
90 948 |
89 981 |
91 680 |
93 028 |
|
91 485 |
|
Net Assets, bln rub |
? |
|
52 551 |
51 483 |
50 214 |
48 024 |
49 463 |
|
48 985 |
|
Debt, bln rub |
|
|
24 114 |
24 364 |
25 024 |
28 516 |
27 961 |
|
28 071 |
|
Cash, bln rub |
|
|
10 573 |
7 959 |
8 005 |
8 965 |
9 220 |
|
8 383 |
|
Net debt, bln rub |
|
|
13 541 |
16 405 |
17 019 |
19 551 |
18 741 |
|
19 688 |
|
|
Ordinary share price, rub |
|
|
104.4 |
91.0 |
79.7 |
84.2 |
83.3 |
|
79.3 |
|
Number of ordinary shares, mln |
|
|
|
|
|
|
1 282 |
|
1 282 |
|
|
Market cap, bln rub |
|
|
0 |
0 |
0 |
0 |
106 800 |
|
101 696 |
|
EV, bln rub |
? |
|
13 541 |
16 405 |
17 019 |
19 551 |
125 541 |
|
121 384 |
|
Book value, bln rub |
|
|
-3 545 |
-4 786 |
-3 997 |
-5 380 |
-3 270 |
|
-3 242 |
|
|
EPS, rub |
? |
|
|
|
|
|
3.74 |
|
2.77 |
|
FCF/share, rub |
|
|
|
|
|
|
4.23 |
|
2.61 |
|
BV/share, rub |
|
|
|
|
|
|
-2.55 |
|
-2.53 |
|
|
EBITDA margin, % |
? |
|
|
|
|
|
27.0% |
|
26.7% |
|
Net margin, % |
? |
|
|
|
|
|
13.2% |
|
13.4% |
|
FCF yield, % |
? |
|
0.00% |
0.00% |
0.00% |
0.00% |
5.08% |
|
3.29% |
|
ROE, % |
? |
|
0.00% |
0.00% |
0.00% |
0.00% |
9.70% |
|
7.26% |
|
ROA, % |
? |
|
0.00% |
0.00% |
0.00% |
0.00% |
5.16% |
|
3.89% |
|
|
P/E |
? |
|
|
|
|
|
22.2 |
|
28.6 |
|
P/FCF |
|
|
|
|
|
|
19.7 |
|
30.4 |
|
P/S |
? |
|
|
|
|
|
2.94 |
|
3.83 |
|
P/BV |
? |
|
0.00 |
0.00 |
0.00 |
0.00 |
-32.7 |
|
-31.4 |
|
EV/EBITDA |
? |
|
|
|
|
|
12.8 |
|
17.1 |
|
Debt/EBITDA |
|
|
|
|
|
|
1.91 |
|
2.78 |
|
|
R&D/CAPEX, % |
|
|
|
|
|
|
150.9% |
|
155.5% |
|
|
CAPEX/Revenue, % |
|
|
|
|
|
|
5.24% |
|
5.33% |
|
| Medtronic shareholders |
